Review





Similar Products

selection eighteen individual human serum  (Innovative Research Inc)
94
Innovative Research Inc selection eighteen individual human serum
Selection Eighteen Individual Human Serum, supplied by Innovative Research Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/selection eighteen individual human serum/product/Innovative Research Inc
Average 94 stars, based on 1 article reviews
selection eighteen individual human serum - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier
gene exp lep mm00434759 m1  (Thermo Fisher)
98
Thermo Fisher gene exp lep mm00434759 m1
Gene Exp Lep Mm00434759 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gene exp lep mm00434759 m1/product/Thermo Fisher
Average 98 stars, based on 1 article reviews
gene exp lep mm00434759 m1 - by Bioz Stars, 2026-05
98/100 stars
  Buy from Supplier
diet induced obesity experiment  (Jackson Laboratory)
86
Jackson Laboratory diet induced obesity experiment
Rec2-exendin-4 gene therapy improves metabolic and behavioral functions <t>in</t> <t>diet-induced</t> obesity model (5 months study) (A) Body weight. (B) Total weight gain of 5 months. (C) Average food intake measured week 1–5 post AAV injection. (D) Absolute fat mass and absolute lean mass at 5 weeks post AAV injection. (E) Relative fat mass and relative lean mass at 5 weeks post AAV injection. (F) Glucose tolerance test at 6 weeks post AAV injection. (G) Area under the curve of the glucose tolerance test. (H) Open field test at 13 weeks post AAV injection. (I) Novel object recognition test at 13 weeks post AAV injection. (J) H&E staining of livers. Data are means ± SEM. Sample size: n = 5 per group. Individual values are shown in graph. Time course data (body weights and GTT) were analyzed using two-way RM-ANOVA with Sidak’s multiple comparisons test. Unpaired t test for other data analyses. ∗ p < 0.05, ∗∗ p < 0.01 , ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. Scale bars, 100 μm.
Diet Induced Obesity Experiment, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/diet induced obesity experiment/product/Jackson Laboratory
Average 86 stars, based on 1 article reviews
diet induced obesity experiment - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
pooled human serum  (Innovative Research Inc)
94
Innovative Research Inc pooled human serum
Rec2-exendin-4 gene therapy improves metabolic and behavioral functions <t>in</t> <t>diet-induced</t> obesity model (5 months study) (A) Body weight. (B) Total weight gain of 5 months. (C) Average food intake measured week 1–5 post AAV injection. (D) Absolute fat mass and absolute lean mass at 5 weeks post AAV injection. (E) Relative fat mass and relative lean mass at 5 weeks post AAV injection. (F) Glucose tolerance test at 6 weeks post AAV injection. (G) Area under the curve of the glucose tolerance test. (H) Open field test at 13 weeks post AAV injection. (I) Novel object recognition test at 13 weeks post AAV injection. (J) H&E staining of livers. Data are means ± SEM. Sample size: n = 5 per group. Individual values are shown in graph. Time course data (body weights and GTT) were analyzed using two-way RM-ANOVA with Sidak’s multiple comparisons test. Unpaired t test for other data analyses. ∗ p < 0.05, ∗∗ p < 0.01 , ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. Scale bars, 100 μm.
Pooled Human Serum, supplied by Innovative Research Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pooled human serum/product/Innovative Research Inc
Average 94 stars, based on 1 article reviews
pooled human serum - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier
obese zucker zdf fa fa male rats  (Charles River Laboratories)
86
Charles River Laboratories obese zucker zdf fa fa male rats
Rec2-exendin-4 gene therapy improves metabolic and behavioral functions <t>in</t> <t>diet-induced</t> obesity model (5 months study) (A) Body weight. (B) Total weight gain of 5 months. (C) Average food intake measured week 1–5 post AAV injection. (D) Absolute fat mass and absolute lean mass at 5 weeks post AAV injection. (E) Relative fat mass and relative lean mass at 5 weeks post AAV injection. (F) Glucose tolerance test at 6 weeks post AAV injection. (G) Area under the curve of the glucose tolerance test. (H) Open field test at 13 weeks post AAV injection. (I) Novel object recognition test at 13 weeks post AAV injection. (J) H&E staining of livers. Data are means ± SEM. Sample size: n = 5 per group. Individual values are shown in graph. Time course data (body weights and GTT) were analyzed using two-way RM-ANOVA with Sidak’s multiple comparisons test. Unpaired t test for other data analyses. ∗ p < 0.05, ∗∗ p < 0.01 , ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. Scale bars, 100 μm.
Obese Zucker Zdf Fa Fa Male Rats, supplied by Charles River Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/obese zucker zdf fa fa male rats/product/Charles River Laboratories
Average 86 stars, based on 1 article reviews
obese zucker zdf fa fa male rats - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
high fat diet induced obesity rat model  (Dawley Inc)
86
Dawley Inc high fat diet induced obesity rat model
Rec2-exendin-4 gene therapy improves metabolic and behavioral functions <t>in</t> <t>diet-induced</t> obesity model (5 months study) (A) Body weight. (B) Total weight gain of 5 months. (C) Average food intake measured week 1–5 post AAV injection. (D) Absolute fat mass and absolute lean mass at 5 weeks post AAV injection. (E) Relative fat mass and relative lean mass at 5 weeks post AAV injection. (F) Glucose tolerance test at 6 weeks post AAV injection. (G) Area under the curve of the glucose tolerance test. (H) Open field test at 13 weeks post AAV injection. (I) Novel object recognition test at 13 weeks post AAV injection. (J) H&E staining of livers. Data are means ± SEM. Sample size: n = 5 per group. Individual values are shown in graph. Time course data (body weights and GTT) were analyzed using two-way RM-ANOVA with Sidak’s multiple comparisons test. Unpaired t test for other data analyses. ∗ p < 0.05, ∗∗ p < 0.01 , ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. Scale bars, 100 μm.
High Fat Diet Induced Obesity Rat Model, supplied by Dawley Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/high fat diet induced obesity rat model/product/Dawley Inc
Average 86 stars, based on 1 article reviews
high fat diet induced obesity rat model - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
obese sc dio c57j m mice  (Janvier Labs)
86
Janvier Labs obese sc dio c57j m mice
Rec2-exendin-4 gene therapy improves metabolic and behavioral functions <t>in</t> <t>diet-induced</t> obesity model (5 months study) (A) Body weight. (B) Total weight gain of 5 months. (C) Average food intake measured week 1–5 post AAV injection. (D) Absolute fat mass and absolute lean mass at 5 weeks post AAV injection. (E) Relative fat mass and relative lean mass at 5 weeks post AAV injection. (F) Glucose tolerance test at 6 weeks post AAV injection. (G) Area under the curve of the glucose tolerance test. (H) Open field test at 13 weeks post AAV injection. (I) Novel object recognition test at 13 weeks post AAV injection. (J) H&E staining of livers. Data are means ± SEM. Sample size: n = 5 per group. Individual values are shown in graph. Time course data (body weights and GTT) were analyzed using two-way RM-ANOVA with Sidak’s multiple comparisons test. Unpaired t test for other data analyses. ∗ p < 0.05, ∗∗ p < 0.01 , ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. Scale bars, 100 μm.
Obese Sc Dio C57j M Mice, supplied by Janvier Labs, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/obese sc dio c57j m mice/product/Janvier Labs
Average 86 stars, based on 1 article reviews
obese sc dio c57j m mice - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
non obese diabetic  (Jackson Laboratory)
86
Jackson Laboratory non obese diabetic
Rec2-exendin-4 gene therapy improves metabolic and behavioral functions <t>in</t> <t>diet-induced</t> obesity model (5 months study) (A) Body weight. (B) Total weight gain of 5 months. (C) Average food intake measured week 1–5 post AAV injection. (D) Absolute fat mass and absolute lean mass at 5 weeks post AAV injection. (E) Relative fat mass and relative lean mass at 5 weeks post AAV injection. (F) Glucose tolerance test at 6 weeks post AAV injection. (G) Area under the curve of the glucose tolerance test. (H) Open field test at 13 weeks post AAV injection. (I) Novel object recognition test at 13 weeks post AAV injection. (J) H&E staining of livers. Data are means ± SEM. Sample size: n = 5 per group. Individual values are shown in graph. Time course data (body weights and GTT) were analyzed using two-way RM-ANOVA with Sidak’s multiple comparisons test. Unpaired t test for other data analyses. ∗ p < 0.05, ∗∗ p < 0.01 , ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. Scale bars, 100 μm.
Non Obese Diabetic, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/non obese diabetic/product/Jackson Laboratory
Average 86 stars, based on 1 article reviews
non obese diabetic - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
obesity  (Nissen)
86
Nissen obesity
Rec2-exendin-4 gene therapy improves metabolic and behavioral functions <t>in</t> <t>diet-induced</t> obesity model (5 months study) (A) Body weight. (B) Total weight gain of 5 months. (C) Average food intake measured week 1–5 post AAV injection. (D) Absolute fat mass and absolute lean mass at 5 weeks post AAV injection. (E) Relative fat mass and relative lean mass at 5 weeks post AAV injection. (F) Glucose tolerance test at 6 weeks post AAV injection. (G) Area under the curve of the glucose tolerance test. (H) Open field test at 13 weeks post AAV injection. (I) Novel object recognition test at 13 weeks post AAV injection. (J) H&E staining of livers. Data are means ± SEM. Sample size: n = 5 per group. Individual values are shown in graph. Time course data (body weights and GTT) were analyzed using two-way RM-ANOVA with Sidak’s multiple comparisons test. Unpaired t test for other data analyses. ∗ p < 0.05, ∗∗ p < 0.01 , ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. Scale bars, 100 μm.
Obesity, supplied by Nissen, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/obesity/product/Nissen
Average 86 stars, based on 1 article reviews
obesity - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
non obese diabetic nod cg prkdcscid il2rgtm1wjl  (Jackson Laboratory)
86
Jackson Laboratory non obese diabetic nod cg prkdcscid il2rgtm1wjl
Rec2-exendin-4 gene therapy improves metabolic and behavioral functions <t>in</t> <t>diet-induced</t> obesity model (5 months study) (A) Body weight. (B) Total weight gain of 5 months. (C) Average food intake measured week 1–5 post AAV injection. (D) Absolute fat mass and absolute lean mass at 5 weeks post AAV injection. (E) Relative fat mass and relative lean mass at 5 weeks post AAV injection. (F) Glucose tolerance test at 6 weeks post AAV injection. (G) Area under the curve of the glucose tolerance test. (H) Open field test at 13 weeks post AAV injection. (I) Novel object recognition test at 13 weeks post AAV injection. (J) H&E staining of livers. Data are means ± SEM. Sample size: n = 5 per group. Individual values are shown in graph. Time course data (body weights and GTT) were analyzed using two-way RM-ANOVA with Sidak’s multiple comparisons test. Unpaired t test for other data analyses. ∗ p < 0.05, ∗∗ p < 0.01 , ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. Scale bars, 100 μm.
Non Obese Diabetic Nod Cg Prkdcscid Il2rgtm1wjl, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/non obese diabetic nod cg prkdcscid il2rgtm1wjl/product/Jackson Laboratory
Average 86 stars, based on 1 article reviews
non obese diabetic nod cg prkdcscid il2rgtm1wjl - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier

Image Search Results


Rec2-exendin-4 gene therapy improves metabolic and behavioral functions in diet-induced obesity model (5 months study) (A) Body weight. (B) Total weight gain of 5 months. (C) Average food intake measured week 1–5 post AAV injection. (D) Absolute fat mass and absolute lean mass at 5 weeks post AAV injection. (E) Relative fat mass and relative lean mass at 5 weeks post AAV injection. (F) Glucose tolerance test at 6 weeks post AAV injection. (G) Area under the curve of the glucose tolerance test. (H) Open field test at 13 weeks post AAV injection. (I) Novel object recognition test at 13 weeks post AAV injection. (J) H&E staining of livers. Data are means ± SEM. Sample size: n = 5 per group. Individual values are shown in graph. Time course data (body weights and GTT) were analyzed using two-way RM-ANOVA with Sidak’s multiple comparisons test. Unpaired t test for other data analyses. ∗ p < 0.05, ∗∗ p < 0.01 , ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. Scale bars, 100 μm.

Journal: Molecular Therapy Advances

Article Title: Low dose systemic AAV-exendin-4 gene therapy for Prader-Willi syndrome and dietary obesity

doi: 10.1016/j.omta.2026.201718

Figure Lengend Snippet: Rec2-exendin-4 gene therapy improves metabolic and behavioral functions in diet-induced obesity model (5 months study) (A) Body weight. (B) Total weight gain of 5 months. (C) Average food intake measured week 1–5 post AAV injection. (D) Absolute fat mass and absolute lean mass at 5 weeks post AAV injection. (E) Relative fat mass and relative lean mass at 5 weeks post AAV injection. (F) Glucose tolerance test at 6 weeks post AAV injection. (G) Area under the curve of the glucose tolerance test. (H) Open field test at 13 weeks post AAV injection. (I) Novel object recognition test at 13 weeks post AAV injection. (J) H&E staining of livers. Data are means ± SEM. Sample size: n = 5 per group. Individual values are shown in graph. Time course data (body weights and GTT) were analyzed using two-way RM-ANOVA with Sidak’s multiple comparisons test. Unpaired t test for other data analyses. ∗ p < 0.05, ∗∗ p < 0.01 , ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. Scale bars, 100 μm.

Article Snippet: For diet-induced obesity experiment, C57BL/6 mice were purchased from Jackson Laboratory.

Techniques: Injection, Staining

Rec2-exendin-4 and Rec2-exendin-4-HA reverses diet-induced obesity and associated metabolic dysfunction (A) Body weight. Mixed ANOVA with Sidak’s multiple comparisons test. ∗ p < 0.05 Ex4 and Ex4-HA versus GFP. (B) Final body weight. (C) Weight gain. Two-way RM-ANOVA with Sidak’s multiple comparisons test. ∗∗∗ p < 0.001 Ex4 and Ex4-HA versus GFP. (D) Total weight gain. (E) Average food intake measured week 1–4 post AAV injection. (F) Glucose tolerance test at 6 weeks post AAV injection. (G) Area under the curve of the glucose tolerance test. (H) Indirect calorimetry at 7–8 weeks post injection. Data are means ± SEM. Sample size: GFP n = 4, Ex4 n = 5, Ex4-HA n = 5. Individual values are shown in graph. One-way ANOVA with Tukey’s post hoc test to adjust pairwise comparisons of all groups. ∗ p < 0.05, ∗∗ p < 0.01 , ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.

Journal: Molecular Therapy Advances

Article Title: Low dose systemic AAV-exendin-4 gene therapy for Prader-Willi syndrome and dietary obesity

doi: 10.1016/j.omta.2026.201718

Figure Lengend Snippet: Rec2-exendin-4 and Rec2-exendin-4-HA reverses diet-induced obesity and associated metabolic dysfunction (A) Body weight. Mixed ANOVA with Sidak’s multiple comparisons test. ∗ p < 0.05 Ex4 and Ex4-HA versus GFP. (B) Final body weight. (C) Weight gain. Two-way RM-ANOVA with Sidak’s multiple comparisons test. ∗∗∗ p < 0.001 Ex4 and Ex4-HA versus GFP. (D) Total weight gain. (E) Average food intake measured week 1–4 post AAV injection. (F) Glucose tolerance test at 6 weeks post AAV injection. (G) Area under the curve of the glucose tolerance test. (H) Indirect calorimetry at 7–8 weeks post injection. Data are means ± SEM. Sample size: GFP n = 4, Ex4 n = 5, Ex4-HA n = 5. Individual values are shown in graph. One-way ANOVA with Tukey’s post hoc test to adjust pairwise comparisons of all groups. ∗ p < 0.05, ∗∗ p < 0.01 , ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.

Article Snippet: For diet-induced obesity experiment, C57BL/6 mice were purchased from Jackson Laboratory.

Techniques: Injection